8-K current report · filed Jul 24, 2026

MANNKIND CORP (MNKD) 8-K Current Report: July 24, 2026

Item 3.02Item 8.01Item EX-99.1MNKD overview

Short answer

MANNKIND CORP (MNKD) filed an 8-K current report with the SEC on July 24, 2026 reporting Item 3.02 (Unregistered Sales of Equity Securities), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). $50.0M gross private-placement proceeds from 10,440,838 shares and pre-funded warrants for 2,412,632 shares.

MANNKIND CORP 8-K event analysis

AI summary of each reported item and its exhibits

Item 3.02 · Unregistered Sales of Equity Securities

  • $50.0M gross private-placement proceeds from 10,440,838 shares and pre-funded warrants for 2,412,632 shares
  • $45.0M proceeds earmarked for contingent value-rights payment triggered by FDA approval of Furoscix ReadyFlow
  • Pre-funded warrants carry $0.01 exercise price, no expiration, and cashless-exercise rights
  • Potential dilution of up to 2,412,632 additional shares, subject to a 19.99% beneficial-ownership cap
  • Resale registration statement required within 30 days, improving investor liquidity once effective

Item 8.01 · Other Events

  • FDA approval of Furoscix ReadyFlow for edema treatment in adults with heart failure or chronic kidney disease
  • Expanded eligible patient population beyond heart-failure patients, potentially increasing commercial opportunity
  • Approval supports MannKind’s portfolio expansion in cardiorenal disease and future revenue growth
  • Commercial impact depends on launch timing, reimbursement, physician adoption, and manufacturing capacity

Item EX-99.1 · Exhibit EX-99.1

  • $50 million private placement led by Frazier Life Sciences, strengthening liquidity for corporate needs
  • $45 million earmarked for contingent value rights payment following Furoscix ReadyFlow FDA approval
  • Issuance of 10,440,838 shares plus pre-funded warrants for 2,412,632 shares, creating material dilution
  • Purchase prices of $3.89 per share and $3.88 per warrant, with $0.01 warrant exercise price
  • Resale registration commitment improves investor liquidity but may increase future selling pressure

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other MANNKIND CORP 8-K filings

Get the next MNKD 8-K as it lands

Follow MNKD for push alerts, or ask the research agent what this filing means.